최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Journal of digestive cancer research, v.10 no.1, 2022년, pp.43 - 45
조장호 (가톨릭대학교 인천성모병원 혈액종양내과)
초록이 없습니다.
Kang, Mee Joo, Won, Young-Joo, Lee, Jae Jun, Jung, Kyu-Won, Kim, Hye-Jin, Kong, Hyun-Joo, Im, Jeong-Soo, Seo, Hong Gwan. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2019. Cancer research and treatment : official journal of Korean Cancer Association, vol.54, no.2, 330-344.
Kato, Ken, Cho, Byoung Chul, Takahashi, Masanobu, Okada, Morihito, Lin, Chen-Yuan, Chin, Keisho, Kadowaki, Shigenori, Ahn, Myung-Ju, Hamamoto, Yasuo, Doki, Yuichiro, Yen, Chueh-Chuan, Kubota, Yutaro, Kim, Sung-Bae, Hsu, Chih-Hung, Holtved, Eva, Xynos, Ioannis, Kodani, Mamoru, Kitagawa, Yuko. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. The Lancet. Oncology, vol.20, no.11, 1506-1517.
Shah, Manish A., Kojima, Takashi, Hochhauser, Daniel, Enzinger, Peter, Raimbourg, Judith, Hollebecque, Antoine, Lordick, Florian, Kim, Sung-Bae, Tajika, Masahiro, Kim, Heung Tae, Lockhart, A. Craig, Arkenau, Hendrik-Tobias, El-Hajbi, Farid, Gupta, Mukul, Pfeiffer, Per, Liu, Qi, Lunceford, Jared, Kang, S. Peter, Bhagia, Pooja, Kato, Ken. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus : The Phase 2 KEYNOTE-180 Study. JAMA oncology, vol.5, no.4, 546-.
Kojima, Takashi, Shah, Manish A., Muro, Kei, Francois, Eric, Adenis, Antoine, Hsu, Chih-Hung, Doi, Toshihiko, Moriwaki, Toshikazu, Kim, Sung-Bae, Lee, Se-Hoon, Bennouna, Jaafar, Kato, Ken, Shen, Lin, Enzinger, Peter, Qin, Shu-Kui, Ferreira, Paula, Chen, Jia, Girotto, Gustavo, de la Fouchardiere, Christelle, Senellart, Helene, Al-Rajabi, Raed, Lordick, Florian, Wang, Ruixue, Suryawanshi, Shailaja, Bhagia, Pooja, Kang, S. Peter, Metges, Jean-Philippe. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.38, no.35, 4138-4148.
Sun, Jong-Mu, Shen, Lin, Shah, Manish A, Enzinger, Peter, Adenis, Antoine, Doi, Toshihiko, Kojima, Takashi, Metges, Jean-Philippe, Li, Zhigang, Kim, Sung-Bae, Cho, Byoung Chul, Mansoor, Wasat, Li, Shau-Hsuan, Sunpaweravong, Patrapim, Maqueda, Maria Alsina, Goekkurt, Eray, Hara, Hiroki, Antunes, Luis, Fountzilas, Christos, Tsuji, Akihito, Oliden, Victor Castro, Liu, Qi, Shah, Sukrut, Bhagia, Pooja, Kato, Ken. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. The Lancet, vol.398, no.10302, 759-771.
Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F.S., Schachter, J., Pavlick, A.C., Lewis, K.D., Cranmer, L.D., Blank, C.U., O'Day, S.J., Ascierto, P.A., Salama, A.K.S., Margolin, K.A., Loquai, C., Eigentler, T.K., Gangadhar, T.C., Carlino, M.S., Agarwala, S.S., Moschos, S.J., Sosman, J.A., Goldinger, S.M., Shapira-Frommer, R., Gonzalez, R., Kirkwood, J.M., Wolchok, J.D., Eggermont, A., Li, X.N., Zhou, W., Zernhelt, A.M., Lis, J., Ebbinghaus, S., Kang, S.P., Daud, A.. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. The Lancet. Oncology, vol.16, no.8, 908-918.
Bang, Yung-Jue, Kang, Yoon-Koo, Catenacci, Daniel V., Muro, Kei, Fuchs, Charles S., Geva, Ravit, Hara, Hiroki, Golan, Talia, Garrido, Marcelo, Jalal, Shadia I., Borg, Christophe, Doi, Toshihiko, Yoon, Harry H., Savage, Mary J., Wang, Jiangdian, Dalal, Rita P., Shah, Sukrut, Wainberg, Zev A., Chung, Hyun Cheol. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, vol.22, no.4, 828-837.
Pacheco, Jose M., Camidge, D. Ross, Doebele, Robert C., Schenk, Erin. A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer. Frontiers in oncology, vol.9, 195-.
Zhao, Joseph J., Yap, Dominic Wei Ting, Chan, Yiong Huak, Tan, Benjamin Kye Jyn, Teo, Chong Boon, Syn, Nicholas L., Smyth, Elizabeth C., Soon, Yu Yang, Sundar, Raghav. Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.40, no.4, 392-402.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
저자가 APC(Article Processing Charge)를 지불한 논문에 한하여 자유로운 이용이 가능한, hybrid 저널에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.